Alzamend Neuro Files 8-K with Corporate Updates
Ticker: ALZN · Form: 8-K · Filed: May 8, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, amendment, financials
Related Tickers: ALZN
TL;DR
ALZN filed an 8-K on 5/8/25 covering corporate changes and financials.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on May 8, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial statements/exhibits. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Atlanta, GA.
Why It Matters
This filing indicates significant corporate actions and disclosures by Alzamend Neuro, Inc., which could impact investors' understanding of the company's structure and financial status.
Risk Assessment
Risk Level: low — This is a routine corporate filing (8-K) detailing standard disclosures and amendments, not an event that inherently increases risk.
Key Numbers
- 001-40483 — SEC File Number (Alzamend Neuro's SEC filing identifier)
- 81-1822909 — EIN (Alzamend Neuro's Employer Identification Number)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- May 8, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, GA (location) — Principal executive address
FAQ
What specific amendments were made to Alzamend Neuro's articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What is the nature of the Regulation FD disclosure mentioned in the filing?
The filing states there is a Regulation FD Disclosure, but the specific content of this disclosure is not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific documents are not detailed in the provided text excerpt.
When was Alzamend Neuro, Inc. incorporated?
Alzamend Neuro, Inc. was incorporated in Delaware.
What is Alzamend Neuro's primary business sector?
Alzamend Neuro, Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Alzamend Neuro, Inc. (ALZN).